A novel surgeon credentialing and quality assurance process using transoral surgery for oropharyngeal cancer in ECOG-ACRIN Cancer Research Group Trial E3311
Robert L. Ferris(University of Pittsburgh), Barbara Burtness(Yale University), Michael E. Kupferman(The University of Texas MD Anderson Cancer Center), F. Christopher Holsinger(Stanford University), Mihir R. Patel(Emory University), Rodrigo Bayon(University of Iowa), Eduardo Méndez(University of Washington Medical Center), Yael Flamand(Dana-Farber Cancer Institute), Elin R. Sigurdson(Fox Chase Cancer Center), Harry Quon(Johns Hopkins University), Wayne M. Koch(Johns Hopkins University), Nabil F. Saba(Emory University), Joaquín J. García(Mayo Clinic), Ranee Mehra(University of Maryland, Baltimore), R. Bryan Bell(Takara (United States)), Umamaheswar Duvvuri(City University of New York), Giovana R. Thomas(National Institutes of Health), Bert W. O’Malley(Baylor College of Medicine), Jeremy D. Richmon(Massachusetts Eye and Ear Infirmary), John A. Ridge(Fox Chase Cancer Center), Jay O. Boyle(Memorial Sloan Kettering Cancer Center), Kerry A. Higgins(ECOG-ACRIN Cancer Research Group), Neil D. Gross(The University of Texas MD Anderson Cancer Center), Daniel W. Karakla(Sentara Norfolk General Hospital), James P. Malone(UPMC Central Pa), Benjamin L. Judson(Yale University), Shuli Li(Unknown), Erich M. Sturgis(Baylor College of Medicine), Gregory S. Weinstein(University of Pennsylvania), Michael L. Hinni(Mayo Clinic), Russel B. Smith(Jackson Memorial Hospital), Enver Özer(The Ohio State University Wexner Medical Center), J. Scott Magnuson(AdventHealth Orlando)
Cited by 45
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Exome Sequencing of Head and Neck Squamous Cell Carcinoma Reveals Inactivating Mutations in <i>NOTCH1</i>
|Science|2011|1.7k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k
Coregulator Function: A Key to Understanding Tissue Specificity of Selective Receptor Modulators
|Endocrine Reviews|2004|924